What we're reading, December 7, 2015: Mylan is subpoenaed over pricing of generic doxycycline antibiotic products; Congressional hearing this week on drug pricing controversy; new superbug on the rise; and Obamacare penalty for being uninsured may not be enough to get people to sign up.
Mylan is the latest company to face federal scrutiny over drug pricing. The Department of Justice has subpoenaed the company in regards to the pricing and marketing of its generic doxycycline antibiotic products, according to Reuters. The decades-old antibiotic is used to treat acne, pneumonia, Lyme disease, chlamydia, syphilis, and more.
Soaring drug prices continue to dominate the news with a Congressional hearing this week that will focus on the price hikes for several medicines. The Senate Special Committee on Aging has been investigating the new tactic of companies to purchase drugs already on the market and then raise the price, reported The Wall Street Journal.
The US is also facing the rise of a dangerous superbug that has been dubbed “phantom menace.” The superbug belongs to a family of bacteria known as CRE, which is often resistant to most antibiotics and often deadly, too, The Washington Post reported. Up to half of patients who become infected die from the bacteria.
Lastly, the penalty for remaining uninsured will increase a third and final time, but critics claim the penalty still won’t be enough to prod millions of Americans to purchase health coverage, according to a report from the Washington Examiner. The fine in 2016 will be $695 or 2.5% of taxable income, whichever is greater.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More